Research programme: Alzheimer's disease therapeutics - Axxam/Alzheimer's Drug Discovery Foundation
Latest Information Update: 16 Jul 2016
At a glance
- Originator Axxam
- Class Small molecules
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in Italy
- 28 Dec 2014 Research programme: Alzheimer's disease therapeutics - Axxam/Alzheimer's Drug Discovery Foundation is available for partnering as of 28 Dec 2014. http://www.axxam.com
- 22 Jun 2011 Early research in Alzheimer's disease in Italy (unspecified route)